Joseph Leveque has joined Armo BioSciences as chief medical officer. Leveque will oversee the late-stage clinical testing of Armo’s lead cancer immunotherapy candidate, as well as the rest of the Redwood City, CA, company’s pipeline. Before Armo, Leveque held executive and senior management roles at EMD Serono, Merck Group, Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), Onyx Pharmaceuticals, Cephalon Oncology, and Amgen (NASDAQ: [[ticker:AMGN]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
